Complex Peripheral Vascular Device Market Size, Share & Trends Analysis | Global | 2025-2032 | Includes: PV Stents, PTA Balloon Catheters, Drug-Coated Balloons (DCBs), and 8 more

Global Complex Peripheral Vascular Device Market Report

The global complex peripheral vascular device market was valued at $10.4 billion in 2025. This market is expected to grow at a CAGR of 5.2% over the forecast period, reaching over $14.8 billion by 2032.

The full report suite covers the global market for complex peripheral vascular devices, including peripheral vascular stents, percutaneous transluminal angioplasty balloon catheters, drug-coated balloons, atherectomy devices, intravascular lithotripsy systems, chronic total occlusion devices, surgical grafts, stent grafts, embolic protection devices, peripheral thrombus management devices and peripheral intravascular ultrasound catheters. Across these categories, the report provides detailed analysis of unit sales, average selling prices, procedure numbers, market size, growth trends, market forecasts through 2032 and historical data to 2022. It also includes market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and analysis of leading competitors.

For this market, growth is being driven by a rising burden of peripheral arterial disease, deep vein thrombosis and venous insufficiency, along with broader use of minimally invasive treatment pathways. Aging populations, higher chronic disease prevalence and continued innovation in stent design, drug delivery and endovascular techniques are supporting steady expansion across both arterial and venous categories.

Market Overview

The global complex peripheral vascular device market includes a broad range of endovascular and surgical products used to diagnose and treat arterial and venous disease outside the heart. These devices are used across multiple clinical settings to manage conditions such as peripheral arterial disease, aortic disease, deep vein thrombosis, chronic venous obstruction and thrombotic occlusions.

The market continues to grow because vascular disease is becoming a larger global clinical burden. As populations age, the number of patients living with diabetes, obesity, hypertension and other cardiovascular risk factors also rises. These factors increase the incidence of vascular disease and expand the number of patients who may require intervention. At the same time, greater awareness of limb preservation, earlier diagnosis and better imaging are helping identify treatable cases that may previously have gone unmanaged.

A major change in this market is the continued shift toward minimally invasive treatment. Endovascular approaches are now used across a wider range of lesion types, including highly calcified disease, chronic total occlusions and complex aortic repair. As a result, demand is increasing not just for standard angioplasty and stenting, but also for more advanced categories such as atherectomy, intravascular lithotripsy, drug-coated balloons, thrombectomy and peripheral IVUS.

Market Drivers

One of the strongest drivers of the global complex peripheral vascular device market is the growth of the venous treatment segment. As physicians gain more training and clinical confidence in diagnosing and treating venous disease, venous intervention is becoming a more distinct area of practice. Conferences and training programs are dedicating more time to venous pathology, which is helping broaden procedural adoption. Because deep vein thrombosis and pulmonary embolism remain significant causes of morbidity and mortality worldwide, the need for better thrombectomy devices, more specialized venous stents and stronger imaging support is growing. This creates both a clinical need and a major market opportunity.

Combination therapies are an important growth driver. In more complex peripheral interventions, physicians are increasingly using multiple device categories in sequence rather than relying on a single treatment type. Below-the-knee treatment is one of the clearest examples. In many cases, treatment has shifted away from using only stents and toward a combination of atherectomy and drug-coated balloon angioplasty. While optimal clinical strategy continues to evolve, this shift raises the average value of each procedure because multiple premium devices are used together. This trend is contributing directly to overall market growth.

Advances in technology also continue to support expansion. Improved stent designs, drug-eluting technologies and endovascular techniques are giving physicians more options and improving procedural outcomes. Intravascular lithotripsy is expanding the ability to treat heavily calcified lesions, while peripheral IVUS helps guide more precise vessel sizing and treatment planning. These improvements increase the confidence of physicians treating more complex disease and support further device adoption.

Market Limiters

Despite the positive long-term outlook, the global complex peripheral vascular device market faces several important limiters.

One major limiter is the impact of clinical evidence evaluations. While strong clinical evidence can create new market opportunities and improve patient care, negative data can quickly change physician behavior and reduce device usage. Several peripheral vascular categories have experienced this challenge. Safety or effectiveness concerns in areas such as paclitaxel use, renal stenting and carotid stenting have affected confidence and slowed growth. Even when the impact on the full market is limited, companies still face greater pressure to produce better data and support broader post-market follow-up.

Regulatory burden is also increasing. As clinical evidence requirements become stricter, manufacturers must spend more time and money gathering, compiling and submitting updated data. This is especially relevant in markets affected by the transition to more demanding regulatory frameworks, including the European Medical Device Regulation environment. For large competitors, these requirements increase operational costs. For smaller companies, they can create meaningful barriers to entry or expansion. Across the market as a whole, this places pressure on margins and can slow product launches.

Concerns over paclitaxel use continue to influence the market as well. Following the 2018 Katsanos meta-analysis and the FDA statement issued in early 2019, use of paclitaxel-coated devices experienced a significant decline as physicians reconsidered their treatment choices. Although these technologies remain important in the market, physician caution and the lingering effect of past safety concerns continue to influence utilization patterns. In some settings, providers shifted back toward lower-cost and more traditional treatment techniques, which affected both procedure mix and average pricing.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, company profiles and product portfolios, leading competitors, recent mergers and acquisitions, market growth trends and broader competitive dynamics.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report suite is designed to provide both a high-level view of the total market and detailed category-by-category visibility. It supports commercial planning, strategic benchmarking and product positioning by connecting procedure growth, pricing trends and company performance across the forecast period.

Markets Covered and Segmentation

• The global complex peripheral vascular device market report includes the following segments:

Peripheral Vascular Stent Market

Further segmented into arterial stents and venous stents.

PTA Balloon Catheter Market

Further segmented into standard, high-pressure, large, small and specialty balloon catheters. Unit analysis is also provided by application, including central venous and hemodialysis access, femoral-popliteal, iliac, infra-popliteal, renal, carotid, aorta and other applications.

Drug-Coated Balloon Market

Further segmented by indication into superficial femoral artery and AV access.

Atherectomy Device Market

Further segmented into laser atherectomy devices and mechanical atherectomy disposables.

Intravascular Lithotripsy Market

CTO Device Market

Further segmented into re-entry devices and re-canalization devices.

Surgical Graft Market

Further segmented by indication into lower limb, aorta repair and extra-anatomical bypass.

Stent Graft Market

Further segmented into AAA, fenestrated stent graft and TAA.

Embolic Protection Device Market

Further segmented into carotid, renal and lower limb devices.

Peripheral Thrombus Management Market

Further segmented into traditional thrombectomy devices, pharmacomechanical thrombectomy devices and catheter-directed thrombolysis.

Peripheral IVUS Market

This segmentation reflects the full range of products used in complex peripheral intervention and vascular repair, covering both arterial and venous therapies as well as open and endovascular treatment approaches.

Competitive Analysis

Medtronic is projected to remain the global market leader in 2025. Its leadership is supported by a dominant position in stent grafts and strong performance in drug-coated balloons, CTO devices and embolic protection systems. The company benefits from a large and diverse product portfolio that gives it share in several high-value categories. This also allows Medtronic to use broader commercial relationships to support lower-cost product lines and strengthen its overall market position. Key products supporting its performance include the Admiral IN.PACT drug-coated balloon portfolio and the Endurant and Valiant stent graft families, along with a wide range of peripheral stents and PTA balloons.

W.L. Gore is one of the most important competitors in the global market, with strong participation in stents, surgical grafts and stent grafts. Because these are high-value categories, the company's presence in them gives it substantial weight in the total market. W.L. Gore is expected to continue gaining share over the forecast period as its product lineup expands and sales of VIABAHN devices continue to grow.

Boston Scientific remained the third-largest competitor in the global complex peripheral vascular device market. Its recent acquisitions of Bolt Medical in 2025 and Silk Road Medical in 2024 have strengthened its position, particularly in venous therapy and PTA balloons. Boston Scientific now holds leadership positions in both of these categories and has built one of the more comprehensive portfolios in venous disease management. This puts the company in a strong position to expand its share in the broader market over the coming years.

Overall, the competitive landscape is shaped by portfolio breadth, leadership in premium device categories and the ability to respond to evolving treatment patterns across both arterial and venous disease.

Technology and Practice Trends

Technology and practice trends in the global complex peripheral vascular device market are moving toward more precise, less invasive and more specialized treatment.

Drug-coated balloons continue to play an important role in treating select peripheral lesions, especially where clinicians want to avoid leaving a permanent implant. At the same time, physician caution related to paclitaxel has encouraged closer clinical evaluation and more selective device use.

Atherectomy and drug-coated balloon combination therapy is becoming more common in below-the-knee and other complex lesion types. This reflects a broader trend toward tailored multi-device treatment rather than single-device therapy.

Intravascular lithotripsy is gaining traction because it gives physicians a way to treat calcified lesions more effectively without adding excessive vessel trauma. Peripheral IVUS is also becoming more valuable because it supports better lesion assessment, device sizing and treatment planning.

In venous disease, greater physician specialization is driving interest in dedicated venous stents, thrombectomy systems and supporting imaging technologies. This segment is becoming more important to the total market as treatment volumes rise and device development becomes more focused.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

867 pages of detailed market analysis, data tables and forecasts.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the largest and fastest-growing opportunities within the global complex peripheral vascular device market?

Which segments are benefiting most from the rise in venous intervention, calcified lesion treatment and multi-device therapy?

How are aging populations and growing vascular disease prevalence affecting procedure volumes worldwide?

What impact are paclitaxel concerns, regulatory pressure and clinical evidence requirements having on adoption patterns?

Which companies lead the most valuable device categories, and how are acquisitions reshaping competition?

How are pricing trends, unit volumes and procedure growth influencing total market expansion through 2032?

The Global Complex Peripheral Vascular Device Market Report from iData Research answers these questions with detailed segmentation, forecast modeling, pricing analysis and competitive intelligence. Use it to benchmark market opportunity, evaluate company positioning and support product, commercial and investment strategy.